胆汁淤积
熊去氧胆酸
免疫系统
硼胆酸
医学
炎症
纤维化
免疫学
内科学
受体
兴奋剂
作者
Mengzhi Zou,Aizhen Wang,Jiajie Wei,Heng Cai,Zixun Yu,Luyong Zhang,Xinzhi Wang
标识
DOI:10.1016/j.intimp.2020.107328
摘要
Cholestasis is one of the most common clinical symptom of liver diseases. If patients do not receive effective treatment, cholestasis can evolve into liver fibrosis, cirrhosis and ultimately liver failure requiring liver transplantation. Currently, only ursodeoxycholic acid, obeticholic acid and bezafibrate are FDA-approved drugs, thereby requiring a breakthrough in new mechanisms and therapeutic development. Inflammation is one of the common complications of cholestasis. Hepatic accumulation of toxic hydrophobic bile acids is a highly immunogenic process involving both resident and immigrating immune cells. And the resulting inflammation may further aggravate hepatocyte injury. Though, great investigations have been made in the immune responses during cholestasis, the relationship between immune responses and cholestasis remains unclear. Moreover, scarce reviews summarize the immune responses during cholestasis and the efficacy of therapies on immune response. The main purpose of this paper is to review the existing literature on dysfunctional immune response during cholestasis and the effect of treatment on immune response which may provide an insight for researchers and drug development.
科研通智能强力驱动
Strongly Powered by AbleSci AI